Antibiotic specialist Paratek Pharmaceuticals (NSDQ: PRTK) has secured additional funding from the Biomedical Advanced Research and Development Authority (BARDA) to develop the antibiotic Nuzyra (omadacycline) for anthrax. Specifically, the latest funding will support Paratek’s program to develop the tetracycline-class antibiotic Nuzyra as a post-exposure prophylaxis and pulmonary anthrax treatment. The latest BARDA funding will support…